A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis

被引：1

作者：

Kastritis, Efstathios ^{[1
]}

Matous, Jeffrey, V ^{[2
]}

Abro, Emad Uddin ^{[3
]}

Eves, P. Taylor ^{[4
]}

Zheng, Cheng ^{[5
]}

Fiorino, Tony ^{[4
]}

Berdeja, Jesus ^{[6
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece

[2] Colorado Blood Canc Inst, Denver, CO USA

[3] Princess Alexandra Hosp, Dept Haematol, Brisbane, Qld, Australia

[4] Zentalis Pharmaceut, New York, NY USA

[5] Zentalis Pharmaceut Inc, New York, NY USA

[6] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA

来源：

关键词：

D O I：

10.1182/blood-2022-158617

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4438 / 4439

页数：2

共 22 条